Biogen Inc. (BIIB)
After hours:
| Previous close | 287.52 |
| Open | 288.57 |
| Bid | 283.01 x 900 |
| Ask | 287.00 x 2200 |
| Day's range | 282.52 - 291.01 |
| 52-week range | 187.16 - 311.88 |
| Volume | |
| Avg. volume | 1,204,891 |
| Market cap | 40.843B |
| Beta (5Y monthly) | 0.21 |
| PE ratio (TTM) | 14.46 |
| EPS (TTM) | 19.62 |
| Earnings date | 15 Feb 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 322.26 |
- Motley Fool
Why the FDA's Rejection of Eli Lilly's Alzheimer's Drug Is Actually Great News for the Stock
When the Food and Drug Administration (FDA) rejects a key drug from a healthcare company, it can send the stock spiraling into a sell-off. In order for the FDA to be confident in a drug's effectiveness, it needs to have a large enough sample size to evaluate it. Unfortunately, in Eli Lilly's case, it simply didn't have enough data points for the agency to make a positive conclusion about the treatment and grant it accelerated approval.
- Zacks
Biogen Inc. (BIIB) Dips More Than Broader Markets: What You Should Know
Biogen Inc. (BIIB) closed at $285.94 in the latest trading session, marking a -1.43% move from the prior day.
- GlobeNewswire
Lecanemab Receives Priority Review Status in Japan
TOKYO and CAMBRIDGE, Mass., Jan. 29, 2023 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced today that an application for manufacturing and marketing approval for lecanemab (generic name, U.S. brand name: LEQEMBI™), an anti-amyloid-β (Aβ) protofibril* antibody, in Japan has been designated for Priority Review by the Japanese Minis
